Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…
Filter posts by:
Blog
Rise with the Waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future
Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to...
Blog
Rise with the Waves: Canada – A Coming (R)evolution: Transforming Pharmaceutical Market Access
Executive Summary Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into...
Blog
Using Transparency in Coverage Reimbursement Insights to Inform Payer and Provider Contracting Strategy
Executive Summary “Transparency in Coverage” (TIC) data is a newer data source that has recently become available for mining unique insights in the reimbursement/economics between payers and providers. In 2020, the Federal Government TIC Rule required health insurers and group health...
Blog
Rise with the Waves: Italy – AIFA Restructuring and Budget Reforms – Stepping into a New (Uncertain) Future?
Executive Summary The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the...
Blog
Rise with the Waves: Germany – A Tale of Two High Impact Policies Shaping Pharma’s Future
Executive Summary Multiple cost-containment reforms, such as the introduction of a 20% rebate on brand-brand combinations and a temporary increase in the mandatory rebate on drugs to 12%, were implemented under Germany’s ‘Financial Stabilization of Statutory Health Insurance System’ Act (GKV-Finanzstabilisierungsgesetz)...
Blog
Cell and Gene Therapies: Six Global Trends We Are Watching in 2024
2023 was a busy year for cell and gene therapies (C>). There were regulatory approvals in the U.S. and EU, including both in rare pediatric conditions with no current effective options (e.g., Duchenne muscular dystrophy (DMD)), as well as in indications...
